OPKO Health, Inc. (OPK)
USD 1.46
(-4.58%)
USD 1.46
(-4.58%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -157.02 Million USD | 35.8% |
| 2022 | -246.2 Million USD | -416.14% |
| 2021 | -47.7 Million USD | -182.67% |
| 2020 | 57.7 Million USD | 129.35% |
| 2019 | -196.6 Million USD | -14.84% |
| 2018 | -171.2 Million USD | 38.07% |
| 2017 | -276.44 Million USD | -277.14% |
| 2016 | -73.3 Million USD | 25.58% |
| 2015 | -98.5 Million USD | 32.44% |
| 2014 | -145.8 Million USD | -83.09% |
| 2013 | -79.63 Million USD | -113.67% |
| 2012 | -37.26 Million USD | -60.72% |
| 2011 | -23.18 Million USD | -108.23% |
| 2010 | -11.13 Million USD | 60.26% |
| 2009 | -28.02 Million USD | 27.34% |
| 2008 | -38.56 Million USD | 85.6% |
| 2007 | -267.85 Million USD | -23880.21% |
| 2006 | -1.11 Million USD | 22.32% |
| 2005 | -1.43 Million USD | 29.89% |
| 2004 | -2.05 Million USD | 45.04% |
| 2003 | -3.73 Million USD | 58.63% |
| 2002 | -9.02 Million USD | 14.24% |
| 2001 | -10.51 Million USD | -22.25% |
| 2000 | -8.6 Million USD | -107.28% |
| 1999 | -4.15 Million USD | -38.37% |
| 1998 | -3 Million USD | 9.09% |
| 1997 | -3.3 Million USD | -10.0% |
| 1996 | -3 Million USD | -36.36% |
| 1995 | -2.2 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -71.47 Million USD | -3.43% |
| 2024 Q2 | -61.67 Million USD | 13.71% |
| 2023 Q2 | 7.02 Million USD | 123.03% |
| 2023 FY | -158.05 Million USD | 35.8% |
| 2023 Q4 | -69.1 Million USD | -7.3% |
| 2023 Q3 | -64.4 Million USD | -1016.73% |
| 2023 Q1 | -30.5 Million USD | 48.39% |
| 2022 Q1 | -72.53 Million USD | -14.94% |
| 2022 FY | -246.2 Million USD | -416.14% |
| 2022 Q3 | -88.57 Million USD | -724.79% |
| 2022 Q4 | -59.1 Million USD | 33.28% |
| 2022 Q2 | -10.73 Million USD | 85.19% |
| 2021 Q1 | 38.43 Million USD | -22.03% |
| 2021 Q2 | 5.57 Million USD | -85.51% |
| 2021 Q3 | 37.82 Million USD | 578.98% |
| 2021 Q4 | -63.1 Million USD | -266.82% |
| 2021 FY | -47.7 Million USD | -182.67% |
| 2020 FY | 57.7 Million USD | 129.35% |
| 2020 Q4 | 49.3 Million USD | 124.71% |
| 2020 Q2 | 27.17 Million USD | 166.68% |
| 2020 Q3 | 21.93 Million USD | -19.28% |
| 2020 Q1 | -40.76 Million USD | 63.77% |
| 2019 Q3 | -39.01 Million USD | 17.45% |
| 2019 Q1 | -75.3 Million USD | 16.33% |
| 2019 Q2 | -47.26 Million USD | 37.24% |
| 2019 Q4 | -112.5 Million USD | -188.38% |
| 2019 FY | -196.6 Million USD | -14.84% |
| 2018 Q1 | -42.6 Million USD | 72.27% |
| 2018 Q3 | -33.46 Million USD | -555.13% |
| 2018 FY | -171.2 Million USD | 38.07% |
| 2018 Q4 | -90 Million USD | -168.95% |
| 2018 Q2 | -5.1 Million USD | 88.01% |
| 2017 Q3 | -58.29 Million USD | -120.44% |
| 2017 FY | -276.44 Million USD | -277.14% |
| 2017 Q4 | -153.6 Million USD | -163.51% |
| 2017 Q2 | -26.44 Million USD | 36.6% |
| 2017 Q1 | -41.7 Million USD | 17.25% |
| 2016 Q4 | -50.4 Million USD | -112.66% |
| 2016 Q3 | -23.7 Million USD | -183.85% |
| 2016 Q1 | -27.51 Million USD | -248.33% |
| 2016 Q2 | 28.26 Million USD | 202.72% |
| 2016 FY | -73.3 Million USD | 25.58% |
| 2015 Q2 | -25.4 Million USD | 55.36% |
| 2015 Q4 | -7.9 Million USD | 3.93% |
| 2015 FY | -98.5 Million USD | 32.44% |
| 2015 Q1 | -56.91 Million USD | -75.12% |
| 2015 Q3 | -8.22 Million USD | 67.64% |
| 2014 Q2 | -34.88 Million USD | -15.22% |
| 2014 FY | -145.8 Million USD | -83.09% |
| 2014 Q4 | -32.5 Million USD | 32.57% |
| 2014 Q1 | -30.27 Million USD | 15.58% |
| 2014 Q3 | -48.2 Million USD | -38.17% |
| 2013 Q2 | -17.98 Million USD | -165.51% |
| 2013 Q3 | -19.01 Million USD | -5.71% |
| 2013 Q1 | -6.77 Million USD | 30.26% |
| 2013 FY | -79.63 Million USD | -113.67% |
| 2013 Q4 | -35.86 Million USD | -88.67% |
| 2012 Q1 | -8.84 Million USD | -4.39% |
| 2012 Q2 | -9.34 Million USD | -5.58% |
| 2012 Q3 | -9.36 Million USD | -0.3% |
| 2012 FY | -37.26 Million USD | -60.72% |
| 2012 Q4 | -9.71 Million USD | -3.66% |
| 2011 Q3 | -5.8 Million USD | -12.44% |
| 2011 FY | -23.18 Million USD | -108.23% |
| 2011 Q4 | -8.47 Million USD | -46.02% |
| 2011 Q1 | -5.08 Million USD | -470.18% |
| 2011 Q2 | -5.16 Million USD | -1.49% |
| 2010 Q2 | -5.52 Million USD | -35.93% |
| 2010 Q1 | -4.06 Million USD | 51.23% |
| 2010 FY | -11.13 Million USD | 60.26% |
| 2010 Q4 | -892 Thousand USD | 86.77% |
| 2010 Q3 | -6.74 Million USD | -22.02% |
| 2009 Q3 | -5.85 Million USD | -11.57% |
| 2009 Q4 | -8.33 Million USD | -42.42% |
| 2009 Q1 | -8.58 Million USD | 7.53% |
| 2009 FY | -28.02 Million USD | 27.34% |
| 2009 Q2 | -5.24 Million USD | 38.86% |
| 2008 Q4 | -9.28 Million USD | -16.29% |
| 2008 FY | -38.56 Million USD | 85.6% |
| 2008 Q1 | -10.63 Million USD | -18.97% |
| 2008 Q2 | -10.66 Million USD | -0.35% |
| 2008 Q3 | -7.98 Million USD | 25.19% |
| 2007 Q1 | -12 Thousand USD | 97.48% |
| 2007 Q4 | -8.93 Million USD | -603.78% |
| 2007 Q3 | 1.77 Million USD | 116.47% |
| 2007 Q2 | -10.77 Million USD | -89675.0% |
| 2007 FY | -267.85 Million USD | -23880.21% |
| 2006 Q4 | -477 Thousand USD | -70.36% |
| 2006 FY | -1.11 Million USD | 22.32% |
| 2006 Q1 | -188 Thousand USD | 56.28% |
| 2006 Q2 | -170 Thousand USD | 9.57% |
| 2006 Q3 | -280 Thousand USD | -64.71% |
| 2005 Q3 | -194 Thousand USD | 59.92% |
| 2005 FY | -1.43 Million USD | 29.89% |
| 2005 Q4 | -430 Thousand USD | -121.65% |
| 2005 Q1 | -331 Thousand USD | -2.48% |
| 2005 Q2 | -484 Thousand USD | -46.22% |
| 2004 FY | -2.05 Million USD | 45.04% |
| 2004 Q4 | -323 Thousand USD | 19.05% |
| 2004 Q3 | -399 Thousand USD | 28.75% |
| 2004 Q2 | -560 Thousand USD | 27.18% |
| 2004 Q1 | -769 Thousand USD | -205.49% |
| 2003 Q2 | -1.84 Million USD | -73.63% |
| 2003 Q3 | -1.55 Million USD | 15.67% |
| 2003 Q4 | 729 Thousand USD | 146.88% |
| 2003 Q1 | -1.06 Million USD | 50.56% |
| 2003 FY | -3.73 Million USD | 58.63% |
| 2002 Q4 | -2.14 Million USD | 24.39% |
| 2002 Q2 | -2.06 Million USD | -4.72% |
| 2002 Q1 | -1.96 Million USD | 16.64% |
| 2002 Q3 | -2.84 Million USD | -37.78% |
| 2002 FY | -9.02 Million USD | 14.24% |
| 2001 Q3 | -3.04 Million USD | 8.27% |
| 2001 FY | -10.51 Million USD | -22.25% |
| 2001 Q1 | -1.79 Million USD | 4.87% |
| 2001 Q2 | -3.31 Million USD | -84.27% |
| 2001 Q4 | -2.36 Million USD | 22.33% |
| 2000 Q1 | -2.49 Million USD | -117.03% |
| 2000 Q4 | -1.89 Million USD | 23.93% |
| 2000 Q3 | -2.48 Million USD | -43.78% |
| 2000 Q2 | -1.72 Million USD | 30.78% |
| 2000 FY | -8.6 Million USD | -107.28% |
| 1999 Q2 | -800 Thousand USD | 33.33% |
| 1999 Q1 | -1.2 Million USD | -33.33% |
| 1999 FY | -4.15 Million USD | -38.37% |
| 1999 Q3 | -1 Million USD | -25.0% |
| 1999 Q4 | -1.15 Million USD | -15.1% |
| 1998 FY | -3 Million USD | 9.09% |
| 1998 Q3 | -1.1 Million USD | -266.67% |
| 1998 Q2 | -300 Thousand USD | 57.14% |
| 1998 Q1 | -700 Thousand USD | 12.5% |
| 1998 Q4 | -900 Thousand USD | 18.18% |
| 1997 Q1 | -600 Thousand USD | 25.0% |
| 1997 Q2 | -700 Thousand USD | -16.67% |
| 1997 Q3 | -900 Thousand USD | -28.57% |
| 1997 Q4 | -800 Thousand USD | 11.11% |
| 1997 FY | -3.3 Million USD | -10.0% |
| 1996 Q2 | -600 Thousand USD | 0.0% |
| 1996 Q1 | -600 Thousand USD | 0.0% |
| 1996 FY | -3 Million USD | -36.36% |
| 1996 Q3 | -800 Thousand USD | -33.33% |
| 1996 Q4 | -800 Thousand USD | 0.0% |
| 1995 FY | -2.2 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -61.284% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -1333.551% |
| Aspira Women's Health Inc. | -18.85 Million USD | -732.914% |
| Biodesix, Inc. | -41.34 Million USD | -279.81% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -5954.2% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1869.353% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1869.353% |
| Bionano Genomics, Inc. | -215.24 Million USD | 27.05% |
| CareDx, Inc | -101.9 Million USD | -54.093% |
| Check-Cap Ltd. | -19.28 Million USD | -714.129% |
| Castle Biosciences, Inc. | -67.97 Million USD | -130.991% |
| DarioHealth Corp. | -56.18 Million USD | -179.451% |
| Exact Sciences Corporation | -215.01 Million USD | 26.971% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -116.0% |
| Guardant Health, Inc. | -564.72 Million USD | 72.195% |
| ICON Public Limited Company | 956.15 Million USD | 116.422% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 114.312% |
| Illumina, Inc. | -1.06 Billion USD | 85.311% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -1426.97% |
| iSpecimen Inc. | -11.16 Million USD | -1305.821% |
| Standard BioTools Inc. | -76.6 Million USD | -104.988% |
| MDxHealth SA | -27.32 Million USD | -474.6% |
| 23andMe Holding Co. | -321.35 Million USD | 51.138% |
| Medpace Holdings, Inc. | 336.82 Million USD | 146.618% |
| Myriad Genetics, Inc. | -123.7 Million USD | -26.937% |
| Mainz Biomed B.V. | -26.64 Million USD | -489.315% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -1392.491% |
| NeoGenomics, Inc. | -107.73 Million USD | -45.746% |
| Neogen Corporation | 58.66 Million USD | 367.666% |
| Inotiv, Inc. | -81.46 Million USD | -92.758% |
| Natera, Inc. | -446.24 Million USD | 64.813% |
| OpGen, Inc. | -15.68 Million USD | -900.868% |
| Psychemedics Corporation | -2.92 Million USD | -5275.591% |
| Prenetics Global Limited | -52.51 Million USD | -199.01% |
| Prenetics Global Limited | -52.51 Million USD | -199.01% |
| Precipio, Inc. | -7.62 Million USD | -1960.643% |
| Personalis, Inc. | -109.93 Million USD | -42.829% |
| RadNet, Inc. | 98.69 Million USD | 259.094% |
| Sera Prognostics, Inc. | -39.82 Million USD | -294.317% |
| Sotera Health Company | 276.69 Million USD | 156.749% |
| Neuronetics, Inc. | -30.55 Million USD | -413.913% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -3513.0% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -3513.0% |
| Trinity Biotech plc | -27.04 Million USD | -480.592% |
| T2 Biosystems, Inc. | -49.66 Million USD | -216.167% |
| Twist Bioscience Corporation | -220.83 Million USD | 28.895% |
| Exagen Inc. | -22.83 Million USD | -587.573% |